ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
Dow Jones
40.003,59
0,34%
Euro vs US Dollar
1,08955
0,00%
Bitcoin
66.922,61
-0,24%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Achilles Therapeutics PLC (ACHL)

  7. Achilles Therapeutics PLC (ACHL) News

ACHL

Achilles Therapeutics (ACHL)

Achilles Therapeutics PLC
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:ACHL
DatumZeitQuelleÜberschriftSymbolFirma
17/05/202423h15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ACHLAchilles Therapeutics PLC
17/05/202423h00GlobeNewswire Inc.Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price RequirementNASDAQ:ACHLAchilles Therapeutics PLC
08/05/202413h44Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ACHLAchilles Therapeutics PLC
08/05/202413h00GlobeNewswire Inc.Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:ACHLAchilles Therapeutics PLC
04/04/202412h45GlobeNewswire Inc.Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business HighlightsNASDAQ:ACHLAchilles Therapeutics PLC
04/04/202412h30GlobeNewswire Inc.Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host ConditioningNASDAQ:ACHLAchilles Therapeutics PLC
05/02/202413h00GlobeNewswire Inc.Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 ConferenceNASDAQ:ACHLAchilles Therapeutics PLC
01/02/202419h14Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ACHLAchilles Therapeutics PLC
18/12/202313h00GlobeNewswire Inc.Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity PredictionNASDAQ:ACHLAchilles Therapeutics PLC
13/11/202322h36Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ACHLAchilles Therapeutics PLC
13/11/202322h30GlobeNewswire Inc.Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent HighlightsNASDAQ:ACHLAchilles Therapeutics PLC
01/11/202322h26Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ACHLAchilles Therapeutics PLC
22/09/202322h42Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ACHLAchilles Therapeutics PLC
22/09/202322h30GlobeNewswire Inc.Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price RequirementNASDAQ:ACHLAchilles Therapeutics PLC
20/09/202314h45InvestorsHub NewsWirePathways to Progress: How Orphan Drug Designation Sparks Biotech TransformationNASDAQ:ACHLAchilles Therapeutics PLC
17/08/202321h16Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ACHLAchilles Therapeutics PLC
04/08/202313h42Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ACHLAchilles Therapeutics PLC
04/08/202313h00GlobeNewswire Inc.Achilles Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business HighlightsNASDAQ:ACHLAchilles Therapeutics PLC
29/06/202322h04Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:ACHLAchilles Therapeutics PLC
29/06/202322h03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ACHLAchilles Therapeutics PLC
12/06/202314h00GlobeNewswire Inc.Achilles Therapeutics to Present at Upcoming ConferencesNASDAQ:ACHLAchilles Therapeutics PLC
10/05/202314h47Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:ACHLAchilles Therapeutics PLC
10/05/202313h15GlobeNewswire Inc.Achilles Therapeutics Reports First Quarter 2023 Financial Results and Recent Business HighlightsNASDAQ:ACHLAchilles Therapeutics PLC
10/05/202313h00GlobeNewswire Inc.Achilles Therapeutics’ New Immunogenicity Prediction Application of its AI-Powered PELEUS™ Platform Uniquely Identifies the Most Potent T Cell AntigensNASDAQ:ACHLAchilles Therapeutics PLC
26/04/202300h00GlobeNewswire Inc.Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price RequirementNASDAQ:ACHLAchilles Therapeutics PLC
25/04/202313h00GlobeNewswire Inc.Achilles Therapeutics Announces Grant of US Patent Covering the Treatment of Patients with an Immunotherapy Targeting Neoantigens Based on Tumor HLA StatusNASDAQ:ACHLAchilles Therapeutics PLC
17/04/202314h00GlobeNewswire Inc.Achilles Therapeutics to Present at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing SummitNASDAQ:ACHLAchilles Therapeutics PLC
14/02/202322h03Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ACHLAchilles Therapeutics PLC
14/02/202322h02Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ACHLAchilles Therapeutics PLC
13/02/202312h05Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ACHLAchilles Therapeutics PLC
 Showing the most relevant articles for your search:NASDAQ:ACHL

Kürzlich von Ihnen besucht

LSE
0KGR
Ixonos Oyj
LSE
ZTF
Zotefoams
NYSE
ML
MoneyLion
COIN
PROTETH
PROT
TG
HHHA
Homes & Holiday
AMEX
RIGS
RiverFront Strategic Inc...
EU
Y862S
Y862S
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten